A detailed history of Engineers Gate Manager LP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 13,386 shares of VRTX stock, worth $6.73 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
13,386
Previous 12,505 7.05%
Holding current value
$6.73 Million
Previous $5.23 Million 20.03%
% of portfolio
0.15%
Previous 0.14%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $346,065 - $427,751
881 Added 7.05%
13,386 $6.27 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $1.99 Million - $2.18 Million
4,886 Added 64.13%
12,505 $5.23 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $375,928 - $450,105
-1,096 Reduced 12.58%
7,619 $3.1 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $1.83 Million - $1.97 Million
5,422 Added 164.65%
8,715 $3.03 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $244,933 - $274,137
779 Added 30.99%
3,293 $1.16 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $7.87 Million - $8.98 Million
-27,783 Reduced 91.7%
2,514 $792,000
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $7.99 Million - $8.99 Million
27,959 Added 1195.85%
30,297 $8.75 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $759,330 - $847,234
-2,773 Reduced 54.26%
2,338 $677,000
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $505,868 - $629,860
-2,153 Reduced 29.64%
5,111 $1.44 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $592,962 - $698,877
-2,678 Reduced 26.94%
7,264 $1.9 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $5.98 Million - $7.55 Million
-33,802 Reduced 77.27%
9,942 $2.18 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $3.06 Million - $3.42 Million
16,851 Added 62.66%
43,744 $7.94 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $4.56 Million - $5.37 Million
24,300 Added 937.14%
26,893 $5.42 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $2,898 - $3,378
14 Added 0.54%
2,593 $557,000
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $1.91 Million - $2.55 Million
-9,241 Reduced 78.18%
2,579 $610,000
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $2.41 Million - $2.85 Million
9,410 Added 390.46%
11,820 $3.22 Million
Q2 2020

Aug 17, 2020

SELL
$225.48 - $295.8 $4,058 - $5,324
-18 Reduced 0.74%
2,410 $700,000
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $2.59 Million - $3.21 Million
-12,957 Reduced 84.22%
2,428 $578,000
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $1.94 Million - $2.61 Million
11,654 Added 312.36%
15,385 $3.37 Million
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $1.86 Million - $2.09 Million
-11,172 Reduced 74.96%
3,731 $632,000
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $2.45 Million - $2.84 Million
14,903 New
14,903 $2.73 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.